logo of the EU drugs agency

You are viewing archived content

Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the EMCDDA.

Figure INF-6. HCV antibody prevalence among injecting drug users — studies with national and subnational coverage [see all figures in this series...]

Part (iii) New injecting drug users (injecting less than 2 years), 2008 to 2009

Notes:

Black squares are samples with national coverage; blue triangles are samples with subnational (including local or regional) coverage. Differences between countries have to be interpreted with caution owing to different types of settings and/or study methods; national sampling strategies vary.

Data for Portugal, Cyprus, Romania and Slovenia are limited to prevalence among IDUs in treatment and may not be representative of prevalence among IDUs who are not in treatment.

Data for UK is those who began injecting in the survey year or the preceding two calendar years.

Countries are presented by order of increasing prevalence, based on the average of national data or, if not available, of subnational data.

 

Related links:

Statistical bulletin 2010: Figure INF-6 part (iii)

For primary sources, study details and data before 2008, see Table INF-113 and Table INF-0.

See also ‘General notes for interpreting data’ on the Explanatory notes and help page

Sources:

Reitox national focal points

(see the help page for information about formats etc.)

Page last updated: Tuesday, 02 August 2011